No Group> Details
Data display
Real time
  • Indices
20 Minutes delay
  • Share Prices
  • Announcements
Price-sensitive announcements are indicated in red/hot pink colour.
Official Listing Date2004-12-16
IndustryPharmaceuticals, Biotechnology & Life Sciences

Mesoblast is a company focused on developing innovative cellular medicines. The company has established a portfolio of cell-based products with three programs in active Phase 3 clinical studies. Its product candidates under investigation are: MPC-150-IM(for chronic heart failure) 、 MPC-06-ID( for chronic low back pain due to disc degeneration)、
MSC-100-IV(for acute graft versus host disease) and MPC-300-IV( for biologic refractory rheumatoid arthritis and diabetic nephropathy).

Mesoblast was publically listed on the Australian Securities Exchange (ASX:MSB) in December 2004. The Company has a Level 3 American Depositary Receipt program facility and listed on Nasdaq (Nasdaq: MESO) in November 2015.